Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J Newland

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Surgical Oncology|December 9, 2024
Implications of Artificial Intelligence for Colorectal Cancer in Young PopulationsJoel Grunhut, John J Newland, Rebecca Frances Brown
The American Surgeon|January 9, 2020
Dr. Orvar Swenson and the Pull-ThroughJohn J Newland, Katerina Dukleska, Scott Cowan, et al.
The American Surgeon|September 30, 2025
Discovering a Never Event: What to Disclose, When, to Whom, and WhyJohn J Newland, Eric M Krause, Mark D Kligman, et al.
American Journal of Surgery|December 30, 2023
Parental leave policies in general surgery residenciesEmily A Engelbrecht-Wiggans, Margaret H Sundel, John J Newland, et al.
Molecular Carcinogenesis|October 26, 2022
Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotypeXi Chen, Gautam Adhikary, Emily Ma, et al.
Molecular Carcinogenesis|July 18, 2022
The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotypeXi Chen, Gautam Adhikary, John J Newland, et al.
Digestive Diseases and Sciences|September 11, 2024
Association of Race and Postoperative Outcomes in Patients with Inflammatory Bowel DiseaseJohn J Newland, Margaret H Sundel, Kyle W Blackburn, et al.
Diseases of the Colon and Rectum|October 25, 2023
Sex-Based Differences in IBD Surgical OutcomesMargaret H Sundel, John J Newland, Kyle W Blackburn, et al.
Diseases of the Colon and Rectum|May 25, 2026
Trends in Colorectal Dysplasia in Patients with Inflammatory Bowel DiseaseJohn J Newland, Joel Grunhut, Rachael Belcher, et al.
Molecular Cancer Research : MCR|May 25, 2023
Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer PhenotypeXi Chen, Gautam Adhikary, John J Newland, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Surgical Oncology|December 9, 2024
Implications of Artificial Intelligence for Colorectal Cancer in Young PopulationsJoel Grunhut, John J Newland, Rebecca Frances Brown
The American Surgeon|January 9, 2020
Dr. Orvar Swenson and the Pull-ThroughJohn J Newland, Katerina Dukleska, Scott Cowan, et al.
The American Surgeon|September 30, 2025
Discovering a Never Event: What to Disclose, When, to Whom, and WhyJohn J Newland, Eric M Krause, Mark D Kligman, et al.
American Journal of Surgery|December 30, 2023
Parental leave policies in general surgery residenciesEmily A Engelbrecht-Wiggans, Margaret H Sundel, John J Newland, et al.
Molecular Carcinogenesis|October 26, 2022
Sulforaphane inhibits CD44v6/YAP1/TEAD signaling to suppress the cancer phenotypeXi Chen, Gautam Adhikary, Emily Ma, et al.
Molecular Carcinogenesis|July 18, 2022
The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotypeXi Chen, Gautam Adhikary, John J Newland, et al.
Digestive Diseases and Sciences|September 11, 2024
Association of Race and Postoperative Outcomes in Patients with Inflammatory Bowel DiseaseJohn J Newland, Margaret H Sundel, Kyle W Blackburn, et al.
Diseases of the Colon and Rectum|October 25, 2023
Sex-Based Differences in IBD Surgical OutcomesMargaret H Sundel, John J Newland, Kyle W Blackburn, et al.
Diseases of the Colon and Rectum|May 25, 2026
Trends in Colorectal Dysplasia in Patients with Inflammatory Bowel DiseaseJohn J Newland, Joel Grunhut, Rachael Belcher, et al.
Molecular Cancer Research : MCR|May 25, 2023
Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer PhenotypeXi Chen, Gautam Adhikary, John J Newland, et al.
Pageof 2